Respiratory Infections News

Stressors in life can contribute to poor functional, cognitive and neuropsychiatric outcomes up to a year after being hospitalized with COVID-19, researchers reported in the Journal of Neurological Science.

The FDA has granted priority review to a biologics license application for Pfizer’s respiratory syncytial virus vaccine candidate, RSVpreF, for older adults, according to the company.

Many patients with tuberculosis who were potentially eligible for a shorter 4-month therapy were treated with standard 6-month courses, according to a recent study.

Changes in gene expression patterns in the brain associated with natural aging also were observed in the brains of those with severe COVID-19, prompting researchers to emphasize the need for neurological follow-up in recovered individuals.

A nationally representative study demonstrated a wide geographic variation in influenza vaccination for both non-Hispanic white and Hispanic short-stay and long-stay nursing home residents.

Pfizer and BioNTech are seeking an emergency use authorization from the FDA for omicron BA.4/BA.5-adapted bivalent COVID-19 vaccines in children aged 6 months to 4 years.

Influenza, respiratory syncytial virus and COVID-19 have come together to pose a serious health threat this holiday season, according to experts.

Patients with PTSD who were diagnosed with COVID-19 were more likely to be hospitalized or die, compared with those without a psychiatric disorder, researchers reported in Translational Psychiatry.

Hospitalizations for influenza are the highest they have been at this time of year since 2010, the CDC reported Friday.

The ACP has released living, rapid practice points summarizing the best available evidence on the treatment of adults with confirmed mild or moderate COVID-19 in an outpatient setting.